Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance

Merat, Sabrina J.; Bru, Camille; van de Berg, Dorien; Molenkamp, Richard; Tarr, Alexander W.; Koekkoek, Sylvie; Kootstra, Neeltje A.; Prins, Maria; Ball, Jonathan K.; Bakker, Arjen Q.; de Jong, Menno D.; Spits, Hergen; Beaumont, Tim; Schinkel, Janke

doi:10.1016/j.jhep.2019.02.013

All Outputs (3)

An exploration into the entry receptors used by hepatitis C virus in relation to the entry and transmission of equine hepaciviurus A (2019)
Presentation / Conference Contribution
Sohrmann, M., Daly, J., Tarr, A., & Kydd, J. (2019, May). An exploration into the entry receptors used by hepatitis C virus in relation to the entry and transmission of equine hepaciviurus A. Paper presented at 17th UK Hepacivirus and Flavivirus meeting, Rydall Hall, Cumbria, UK

IFITMs mediate viral evasion in acute and chronic hepatitis C virus infection (2019)
Journal Article
Wrensch, F., Ligat, G., Heydmann, L., Schuster, C., Zeisel, M. B., Pessaux, P., …Baumert, T. F. (2019). IFITMs mediate viral evasion in acute and chronic hepatitis C virus infection. Hepatology, 70(5), 1506-1520. https://doi.org/10.1002/hep.30699

While adaptive immune responses against hepatitis C virus (HCV) infection have been studied in great detail, the role of innate immunity in protection against HCV infection and immune evasion is only partially understood. Interferon‐induced transmemb... Read More about IFITMs mediate viral evasion in acute and chronic hepatitis C virus infection.

Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance (2019)
Journal Article
Merat, S. J., Bru, C., van de Berg, D., Molenkamp, R., Tarr, A. W., Koekkoek, S., …Schinkel, J. (2019). Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance. Journal of Hepatology, 71(1), 14-24. https://doi.org/10.1016/j.jhep.2019.02.013

Background & Aims Understanding immune protection against hepatitis C virus (HCV) infection is necessary for designing an effective vaccine. A number of broadly-reactive, neutralizing antibodies have been isolated from B cells of HCV-infected subjec... Read More about Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance.